| dc.contributor.author | Toki, MI | |
| dc.contributor.author | Harrington, K | |
| dc.contributor.author | Syrigos, KN | |
| dc.date.accessioned | 2021-03-23T11:54:54Z | |
| dc.date.available | 2021-03-23T11:54:54Z | |
| dc.date.issued | 2020-08-01 | |
| dc.identifier.citation | Lung cancer (Amsterdam, Netherlands), 2020, 146 pp. 127 - 133 | |
| dc.identifier.issn | 0169-5002 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4435 | |
| dc.identifier.eissn | 1872-8332 | |
| dc.identifier.doi | 10.1016/j.lungcan.2020.04.026 | |
| dc.description.abstract | Spread through air spaces (STAS) was included as a novel pattern of invasion in lung adenocarcinoma by the World Health Organization in 2015. Since then, multiple studies have investigated the association of STAS with clinicopathological and molecular features and its implication in the prognosis of early stage lung cancer patients undergoing different surgery types. The aim of this comprehensive review is to present current data on the role of STAS and its perspective in lung adenocarcinoma management. | |
| dc.format | Print-Electronic | |
| dc.format.extent | 127 - 133 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER IRELAND LTD | |
| dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| dc.title | The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2020-04-22 | |
| rioxxterms.version | AM | |
| rioxxterms.versionofrecord | 10.1016/j.lungcan.2020.04.026 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Lung cancer (Amsterdam, Netherlands) | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.publication-status | Published | |
| pubs.volume | 146 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Targeted Therapy | |
| icr.researchteam | Targeted Therapy | |
| dc.contributor.icrauthor | Harrington, Kevin | |
